Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 721 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07229365Recruiting
Kids' daily activities and vision study
This study looks at what children do every day and how it relates to their vision. It may help understand why some children need glasses.
Bloomington, IndianaAges 7–14 - NCT07230210Recruiting
Nutrition and exercise app study for muscle loss risk
This study tests if a smartphone program can help older adults at risk for muscle loss (sarcopenia) improve their strength and nutrition. You use an app to follow exercise and diet plans at home.
Hualien CityAges 65 years+ - NCT07237685Recruiting
Diabetes and heart artery plaque progression study
This study uses a follow-up CT scan of your heart arteries to see how diabetes-related plaque buildup changes over time. It may help researchers understand how well current diabetes treatments are protecting your heart.
AmsterdamAges 18 years+ - NCT07242963Recruiting
Study of Shh medulloblastoma with U1 mutation
This study looks at people with a certain type of brain tumor called sonic hedgehog medulloblastoma that has come back or not responded to treatment. Researchers want to learn more about these tumors that have a specific genetic change (U1 mutation), which may help find better treatments in the future.
Houston, TexasAges 3–50 - NCT06101277Recruiting
Local therapy for limited new cancer growth in digestive cancers
This trial tests a cancer treatment that uses local therapies (like radiation or targeted heat) to destroy a small number of growing spots. It is for people with certain gastrointestinal cancers whose main treatment is working well except for a few new spots, so they can avoid switching to a different drug right away.
Sacramento, CaliforniaAges 18 years+ - NCT07419334RecruitingPhase 3
Study of a new drug for Stargardt disease
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
Phoenix, ArizonaAges 8–45 - NCT07428447Recruiting
Skin test to predict Parkinson's risk in essential tremor
This study uses a skin biopsy to check for a protein linked to Parkinson's disease. It aims to see if people with essential tremor who have this protein are more likely to develop Parkinson's disease.
Scottsdale, ArizonaAges 50–85 - NCT07256717Recruiting
5-week movement training study for healthy active adults
This study tests a 5-week training program to see if it improves how you move and how your muscles adapt. It may help if you are healthy and already exercise regularly.
Columbus, OhioAges 18–65 - NCT07261657RecruitingEarly Phase 1
N-803 for sarcoma after cell therapy
This trial tests a new drug called N-803 for people with synovial sarcoma or myxoid/round cell liposarcoma whose cancer grew after a prior cell therapy (TCR-T). N-803 aims to boost your immune system to fight the cancer more effectively.
Chicago, IllinoisAges 18–80 - NCT07267117Recruiting
Heart valve disease progression and outcomes study
This study is following people with heart valve disease (leaky or narrowed valves) to understand how the disease changes over time and what problems it may cause. It does not test a new treatment, but helps doctors learn more about valve disease progression.
Fuzhou, FujianAges 18 years+ - NCT07291687Recruiting
Test of tDCS for improving walking
This study tests whether a safe, non-invasive brain stimulation (tDCS) can improve movement and walking in people who have trouble with motor function. You can join if you're able to walk daily, with or without a walking aid, and don't have metal in your brain.
Toronto, OntarioAges Any age - NCT07300696Recruiting
MRI to track lung disease changes in ILD
This study uses MRI scans to monitor how lung scarring changes over time in people with certain types of interstitial lung disease (ILD), like idiopathic pulmonary fibrosis (IPF). The goal is to see if MRI can be a helpful tool for tracking the disease without needing as many CT scans.
HeidelbergAges 18 years+ - NCT07306299RecruitingPhase 1
MRNA vaccine for recurrent high-grade glioma
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hangzhou, ZhejiangAges 16 years+ - NCT07312110RecruitingPhase 2
D-Serine for slowing Parkinson's disease progression
This study tests whether a supplement called D-serine can slow the progression of Parkinson's disease. It is for people diagnosed within the last 5 years who have mild to moderate symptoms and are not yet dependent on a wheelchair.
Arendal, AgderAges 40–80 - NCT07312318Recruiting
AI predicts heart artery changes after stenting
This study uses artificial intelligence to predict how heart arteries might change after a stent procedure (PCI). Researchers will collect blood samples and medical data to develop a tool that could help doctors make better treatment decisions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07316452Recruiting
Early heart disease risk study for adults under 45
This study looks at what makes heart disease progress in younger adults (18 to 45). If you have symptoms of heart disease and have had a heart CT scan, joining this research might help doctors better predict and manage your condition.
BeijingAges 18–45 - NCT07323069Recruiting
Nurse-led sleep program for children with cancer
This trial tests a special nurse-led program to help children with cancer sleep better. It includes simple steps to improve sleep and is designed for kids who are between 6 and 12 years old and currently getting cancer treatment.
Kowloon BayAges 6–12 - NCT07323745RecruitingEarly Phase 1
Mobithron Advance for knee osteoarthritis: long-term effects
This trial tests a supplement called Mobithron Advance to see if it can slow down knee osteoarthritis over time. It may help people with mild to moderate knee arthritis find a non-surgical option.
Kota Bharu, KelantanAges 50 years+ - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT05946564RecruitingPhase 3
Pioglitazone to protect kidney function in ANCA vasculitis
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
AmiensAges 18–80 - NCT07353424Recruiting
Salicornia extract for memory after a small stroke
This study tests whether a polyphenol-rich extract from a salt-tolerant plant called Salicornia can slow memory decline in people who have had a lacunar stroke. It compares the extract to the usual care you would receive.
SevilleAges 40–90
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 721 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.